Day: November 4, 2023

– Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden – – 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 – – Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection – – Ixo-vec continues to be generally well tolerated – – Previously announced aflibercept protein levels from the LUNA study were also presented – REDWOOD CITY, Calif., Nov. 04, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new...

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension studyWell-demonstrated safety profile consistent with previously reported clinical dataApproximately 92% of patients enrolled in GALE completed the first year of the study, demonstrating robust long-term complianceData were presented during an oral presentation at the American Academy of Ophthalmology (AAO) Annual MeetingA Media Snippet accompanying this announcement is available by clicking on this link. WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first-ever FDA-approved treatment for geographic atrophy (GA)...

Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents novel preclinical data of their MDG2011 program lead candidates which are optimal affinity Kirsten rat sarcoma viral oncogene homologue mutation (mKRAS)-specific T cell receptors (TCRs) targeting human leukocyte antigens (HLA) A*11, in combination with a PD1-41BB costimulatory switch protein (CSP) at the Society for Immunotherapy of Cancer (SITC) 2023 November 1-5, 2023, in San Diego, USA. The poster with the title “A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combination with a PD1-41BB armoring and enhancement costimulatory switch receptor”...

Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations provide further safety analysis of Phase 2b and details of pivotal Phase 3 clinical trial design, which is currently enrolling. BRISBANE, Calif., Nov. 04, 2023 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the presentation of three posters – including an additional analysis of week 36 data from the Phase 2b ORIGIN study demonstrating resolution of hematuria in the majority of patients – on the Company’s product candidate atacicept in patients with immunoglobulin...

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillance Application of the enLIGHTEN™ Advanced Analytics suite to datasets from immune checkpoint inhibitor (ICI)-treated patients enabled in silico prediction and subsequent preclinical validation of multi-gene payload combinations to overcome lack of response to ICI Candel’s enLIGHTEN™ Discovery Platform is the first systematic, iterative herpes simplex virus (HSV)-based platform designed to leverage human biology and advanced analytics to create new viral immunotherapies for solid tumorsNEEDHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company...

Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cells BOSTON, Nov. 04, 2023 (GLOBE NEWSWIRE) — Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company’s proprietary nicotinamide (NAM) technology on its allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in San Diego, CA. Both omidubicel and GDA-201 are powered by Gamida Cell’s proprietary NAM technology, which enhances and expands cells to create potentially curative cell therapies for patients with cancer. Omidubicel was approved under the brand name Omisirge™ (omidubicel-onlv)...

CALGARY, Alberta, Nov. 03, 2023 (GLOBE NEWSWIRE) — Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is pleased to announce the signing of a $7.7 million seismic data licensing sales contract. The sale announced today brings 2023 year-to-date seismic data library sales to $30.7 million, a 328% increase over full year 2022 seismic data library sales. This significant data licensing agreement builds upon the Company’s increasing year-over-year data sales, and further improves its strong financial position. Pulse operates with a very lean cost structure and has low capital requirements. Significant sales such as this, produces material incremental free cashflow to Pulse. Currently, Pulse pays a regular quarterly dividend, representing an annualized dividend of $0.055 per share. Additionally, in the third quarter...

VANCOUVER, British Columbia, Nov. 03, 2023 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) further to the press releases dated September 7th, 12th, and 25th 2023, the Company is pleased to announce that it has closed the third tranche and final (the “third Tranche”) of a non-brokered private placement of secured convertible promissory notes (the “Notes”) in the principal amount of CDN$294,000 (the “Offering”). All securities issued pursuant to the Offering are subject to a statutory four-month and one day hold period from the date of issuance pursuant to applicable securities laws of Canada. Proceeds from the Offering will be used for repayment of outstanding debentures, working capital and general corporate purposes. The third tranche...